Intercell kills diarrhea vaccine after study
Page 1 of 1 • Share
Intercell kills diarrhea vaccine after study
[You must be registered and logged in to see this image.]
NEW YORK: Austrian biotech company Intercell said it won't develop its Travelers' Diarrhea vaccine candidate and will post a much wider than expected 2010 loss, because the drug failed in clinical trials.
The company said on Sunday that the patch-based Travelers' Diarrhea vaccine candidate failed to meet efficacy endpoints to protect against enterotoxigenic E. coli mediated diarrheal infections in pivotal, randomized and placebo-controlled efficacy studies.
While it doesn't plan to develop the vaccine anymore, Intercell said the studies support the continued investigation of its patch technology for future vaccines.
It expects its loss for 2010 to be "substantially higher" than its previous forecast of 40 million euros because it will not receive milestone payments in connection with the Travelers' Diarrhea program.
The company said the intangible assets from the vaccine program had a book value of 167 million euros as of September
30. It plans to take a charge to write-down the value of all or a most of those assets that will also hurt the company's 2010 results.
Intercell said it has decided to cut research and development spending by about 40 percent in 2011. It said the company will focus its resources on the other projects in its clinical stage portfolio.
NEW YORK: Austrian biotech company Intercell said it won't develop its Travelers' Diarrhea vaccine candidate and will post a much wider than expected 2010 loss, because the drug failed in clinical trials.
The company said on Sunday that the patch-based Travelers' Diarrhea vaccine candidate failed to meet efficacy endpoints to protect against enterotoxigenic E. coli mediated diarrheal infections in pivotal, randomized and placebo-controlled efficacy studies.
While it doesn't plan to develop the vaccine anymore, Intercell said the studies support the continued investigation of its patch technology for future vaccines.
It expects its loss for 2010 to be "substantially higher" than its previous forecast of 40 million euros because it will not receive milestone payments in connection with the Travelers' Diarrhea program.
The company said the intangible assets from the vaccine program had a book value of 167 million euros as of September
30. It plans to take a charge to write-down the value of all or a most of those assets that will also hurt the company's 2010 results.
Intercell said it has decided to cut research and development spending by about 40 percent in 2011. It said the company will focus its resources on the other projects in its clinical stage portfolio.
Rao Muhammad Aftab- Monstars
-
Posts : 1091
Join date : 2011-02-11
Age : 35
Similar topics
» Honey kills bacteria: study
» Vaccine alliance says 5-in-1 vaccine cost to fall
» Scientists to pave way for Hepatitis C Vaccine
» Scientists developing vaccine for immediate stress relief
» Swine flu survivors offer clues to new vaccine
» Vaccine alliance says 5-in-1 vaccine cost to fall
» Scientists to pave way for Hepatitis C Vaccine
» Scientists developing vaccine for immediate stress relief
» Swine flu survivors offer clues to new vaccine
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
|
|
Yesterday at 10:16 pm by ali001
» Amuse - Become Smarter
Wed May 15, 2024 10:50 am by ali001
» Fort Lock
Sat May 04, 2024 11:49 am by ali001
» house disrepair claims
Thu May 02, 2024 4:29 pm by Ibad Khan Buledi
» Bounce n Bang: Physics puzzler
Thu May 02, 2024 11:39 am by ali001
» AIChatSY - AIChatbot Assistant
Wed May 01, 2024 10:48 am by ali001
» Storybook Magic App
Tue Apr 30, 2024 7:06 pm by ali001
» Flower Book Match3 Puzzle Game
Tue Apr 30, 2024 12:17 pm by ali001
» Avian Influenza Symptom in Chickens "Bird Flu H5N1 Virus" Vet learning materials, Poultry Farming
Sat Apr 27, 2024 9:57 am by Ibad Khan Buledi